Key Points
- Director Blake Borgeson sold 30,000 shares on May 5 at an average price of $3.52 for $105,600 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 0.48% while still owning about 6.2 million shares (~$21.8M).
- Recursion's quarterly results showed EPS of -$0.22 (beating estimates of -$0.30) but revenue plunged 56.8% to $6.47M versus $15.78M expected, leaving the company with severely negative margins and a MarketBeat consensus rating of "Hold" with a $9.20 price target.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the business's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total value of $105,600.00. Following the sale, the director owned 6,199,863 shares of the company's stock, valued at approximately $21,823,517.76. The trade was a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total value of $93,000.00.
Recursion Pharmaceuticals Stock Performance
Shares of NASDAQ:RXRX opened at $3.27 on Friday. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.80 and a 1-year high of $7.18. The stock has a market capitalization of $1.72 billion, a P/E ratio of -2.72 and a beta of 1.05. The business has a 50-day moving average price of $3.40 and a two-hundred day moving average price of $4.12.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.22%. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same quarter last year, the firm earned ($0.50) EPS. The company's revenue for the quarter was down 56.8% on a year-over-year basis. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.08 earnings per share for the current year.
Wall Street Analysts Forecast Growth
RXRX has been the subject of several recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday. Bank of America decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating for the company in a report on Wednesday, February 25th. Wall Street Zen cut shares of Recursion Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Finally, JPMorgan Chase & Co. lowered their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating on the stock in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.20.
Get Our Latest Stock Analysis on Recursion Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company's stock worth $192,998,000 after buying an additional 7,407,606 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after purchasing an additional 3,771,357 shares during the period. State Street Corp lifted its holdings in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company's stock worth $103,616,000 after buying an additional 7,064,963 shares during the period. Geode Capital Management LLC boosted its holdings in Recursion Pharmaceuticals by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company's stock valued at $44,731,000 after acquiring an additional 1,310,695 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at $23,473,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
